| SATURDAY OCT 3 and SUNDAY OCT 4 |
Pre-meeting workshops (click for more info)
|
| |
| SUNDAY OCT 4 |
| 12:00 PM |
5:00 PM |
Registration |
|
| 5:00 PM |
9:00 PM |
ACoP Opening Reception |
|
| |
|
|
|
| MONDAY OCT 5 |
| 7:30 AM |
8:30 AM |
Breakfast/Registration |
|
| 8:30 AM |
8:45 AM |
Opening remarks |
Stacey Tannenbaum |
| 8:45 AM |
10:15 AM |
Applications of Modeling over the Development
Life Cycle of Biologics |
David D'Argenio
Don Mager |
| |
|
Predicting human PK/PD of biologics from animal data |
Peiming Ma |
| |
|
Modeling and simulations for assessment of PK and PD of a G-CSF biosimilar |
Wojciech Krzyzanski |
| |
|
Population PK-PD Modeling of Biological Agents: When Modeling Meets Reality |
Diane Mould |
| 10:15 AM |
11:00 AM |
Break/Poster set up/Software Demos |
|
| 11:00 AM |
12:30 PM |
Model and Data Sharing Initiatives |
Klaus Romero
Brian Corrigan |
| |
|
TIPharma mechnism-based PKPD modeling platform |
Meindert Danhof |
| |
|
The Coalition Against Major Diseases: Review of goals, accomplishments and future plans |
Klaus Romero |
| |
|
OpenDiseaseModels.org: An Open Forum for Collaborative Model Building and Evaluation |
Bill Gillespie |
| |
|
FDA Disease Models |
Christoffer Tornøe |
| 12:30 PM |
2:00 PM |
Lunch |
|
| 2:00 PM |
3:30 PM |
Dealing with Missing Data in Pharmacometrics |
Marc Gastonguay
Jonathan French
|
| |
|
Introduction to Missing data and issues in pharmacometrics |
Jonathan French |
| |
|
When Should We Be Concerned About Nonignorably Missing Data? |
Dan Heitjan |
| |
|
The Impact of Missing Data on Model Evaluation |
Marc Gastonguay |
| 3:30 PM |
5:00 PM |
Break/Posters/Software Demos |
|
| 5:00 PM |
6:00 PM |
Lewis B. Sheiner Memorial Lecture |
|
| |
|
Introduction |
Peter Milligan |
| |
|
Connecting to the Other Side |
Mats Karlsson |
| 6:00 PM |
7:00 PM |
Where will the pharmacometricians of the future come from? |
Hartmut Derendorf
Bernd Meibohm |
| |
|
Panel discussion |
Sandra Allerheiligen, David Cadieu, Amita Joshi, Richard Lalonde
|
| 7:00 PM |
11:00 PM |
ACoP Social Event |
|
| |
|
|
|
| TUESDAY OCT 6 |
| 8:00 AM |
9:00 AM |
Breakfast |
|
| 9:00 AM |
10:30 AM |
Development and utilization of disease models |
Mats Karlsson
Marc Pfister |
| |
|
A Mechanism-Based Disease Model for SGLT2 Inhibitors in Type 2 Diabetes (T2DM) Subjects |
Chee Ng |
| |
|
Empirical Disease Progression Model for Ranibizumab in Age-Related Macular Degeneration |
Satyendra Suryawanshi |
| |
|
The Antiviral Information Management System (AIMS): Leveraging prior knowledge to inform dose selection of new hepatitis C therapies |
Lauren Neal |
| |
|
A Modeling Framework to Simulate Motesanib Efficacy in Thyroid Cancer |
René Bruno |
| 10:30 AM |
11:00 AM |
Break |
|
| 11:00 AM |
12:30 PM |
New Directions in Cardiovascular Modeling: From Biomarkers to Clinical Outcomes and Comparative Effectiveness |
Richard Lalonde
Christine Garnett |
| |
|
The RAAS Hypertension PhysioLab platform: A Systems Modeling Approach to Hypertension |
Ramprasad Ramakrishna |
| |
|
Conceptual Framework for Evaluating The CV Risk Manifested By Drug-Induced Elevations in Systolic Blood Pressure |
Raj Madabushi |
| |
|
Quantitative Approaches for Comparative Effectiveness and Pharmacoeconomics |
Jens Grueger |
| 12:30 PM |
2:00 PM |
Student Session: Troubleshoot your project with M&S experts in small groups |
Diane Mould, David D'Argenio, Leonid Gibiansky, William Gillespie, Luann Phillips |
| 12:30 PM |
7:00 PM |
Afternoon off (on your own) |
|
| 7:00 PM |
8:30 PM |
KEYNOTE PRESENTATION: Beautiful Evidence |
Edward Tufte |
| 8:30PM |
10:00 PM |
Buffet dinner, posters, and exhibitors |
|
| |
|
|
|
| WEDNESDAY OCT 7 |
| 7:00 AM |
8:00 AM |
Breakfast |
|
| 8:00 AM |
9:30 AM |
Communication Through Graphics: Looking at Data, Models, and Results |
Andreas Krause |
| |
|
Exploratory Data Visualisation: Taming the Technology |
Richard Pugh |
| |
|
Visualizing PK/PD Models using Berkeley Madonna |
Andreas Krause |
| |
|
Simulation Graphics to Enable Model-Based Decision Making |
Kevin Dykstra |
| 9:30 AM |
11:00 AM |
Break/Posters/Software Demos |
|
| 11:00 AM |
1:00 PM |
Event Driven/Non-continuous Data Models |
Raymond Miller
Celine Dartois Sarr
|
| |
|
Exposure-Response Analysis for Spontaneously Reported Dizziness in Pregabalin Treated Patients with Generalized Anxiety Disorder |
Kaori Ito |
| |
|
Impact of Dosing Regimens on Dropout Across Pregabalin Trials in the Treatment of Generalized Anxiety Disorder |
Bojan Lalovic |
| |
|
Apnea of prematurity: A mixed effects modeling approach to disease resolution and pharmacologic intervention modeling |
Christopher J Godfrey |
| |
|
Estimation of Mixed Hidden Markov Models with SAEM. Application to daily seizures data. |
Marc Lavielle |
| 1:00 PM |
2:00 PM |
Lunch |
| 2:00 PM |
3:30 PM |
Who Wants to Be the First to Dose this Drug in Children? Approaches to Use Knowledge to Inform Dosing Choices |
Steven Kern |
| |
|
The Design and Analysis of Informative Pediatric Clinical Pharmacology Trials Based on Integrating Modeling and Simulation With Available Prior Knowledge
|
Jeff Barrett |
| |
|
No Experience, No Problem: Using Bottom-up Approaches to Guide First-in-Children Dosing |
Andrea Edginton |
| |
|
Evaluation of Performance of a Pediatric Pharmacokinetic Study Using a Simulation Based Design |
Manisha Lamba |
| 3:30 PM |
4:30 PM |
Break/Posters/Software Demos |
|
| 4:30 PM |
5:45 PM |
PhRMA working group updates |
Julie Stone
Amit Roy |
| |
|
Adaptive Dose-Ranging Studies: An Update from the PhRMA Working Group |
Jose Pinheiro |
| |
|
Optimizing TQT Studies through PK-PD: An OQT Working Group |
Larisa Reyderman |
| |
|
Model-Based Drug Development PhRMA Initiative: Mapping the current status and future state for modeling and simulation in the pharmaceutical industry |
Julie Stone |
| 5:45 PM |
6:00 PM |
Closing remarks |
ACoP committee |
| |
|
|
|
| THURSDAY OCT 8 |
Post-meeting workshops (click for more info)
|